aTyr Pharma (ATYR) Proxy filing summary

Executive summary

• Special Meeting scheduled for October 16, 2026, to vote on a reverse stock split proposal at a ratio between 1-for-10 and 1-for-50, at the Board's discretion.

• The reverse stock split aims to help maintain compliance with Nasdaq's $1.00 minimum bid price requirement and improve stock marketability and liquidity.

• Board retains authority to implement, select the ratio, or abandon the reverse split within one year of approval.

• No fractional shares will be issued; fractional entitlements will be rounded up to the nearest whole share.

• The par value per share remains unchanged, and the split will not affect percentage ownership except for rounding.

Voting matters and shareholder proposals

• Only one proposal is up for vote: approval of alternate amendments to effect a reverse stock split at a ratio between 1-for-10 and 1-for-50.

• Board unanimously recommends voting "FOR" the reverse stock split proposal.

• Shareholders may submit proposals for the 2027 Annual Meeting by November 26, 2026, for inclusion in the proxy statement.

Board of directors and corporate governance

• Board has full discretion to determine whether and when to implement the reverse split and at what ratio within the approved range.

• Board may abandon the reverse split even after shareholder approval.